Published in Prostate Cancer Prostatic Dis on January 01, 2002
Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest (2006) 1.81
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer (2003) 1.25
Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia. Int Neurourol J (2014) 0.99
Retracted Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms. BMC Surg (2012) 0.90
The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother (2004) 0.88
New treatments for chronic prostatitis/chronic pelvic pain syndrome. Nat Rev Urol (2010) 0.87
Various treatment options for benign prostatic hyperplasia: A current update. J Midlife Health (2012) 0.86
Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opin Ther Targets (2011) 0.84
Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol (2011) 0.83
Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One (2009) 0.81
β-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors. World J Urol (2011) 0.81
Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. PLoS One (2012) 0.80
New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol (2015) 0.80
Evaluation of discoidin domain receptor-2 (DDR2) expression level in normal, benign, and malignant human prostate tissues. Res Pharm Sci (2015) 0.77
Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection. BMC Urol (2012) 0.76
Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.76
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers. Int J Mol Sci (2016) 0.75
Label-Free Dynamic Mass Redistribution Reveals Low-Density, Prosurvival α1B-Adrenergic Receptors in Human SW480 Colon Carcinoma Cells. J Pharmacol Exp Ther (2017) 0.75
Transforming growth factor-beta type I receptor/ALK5 contributes to doxazosin-induced apoptosis in H9C2 cells. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.75
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proc Natl Acad Sci U S A (1991) 1.63
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res (2001) 1.35
Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol (1996) 1.30
bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology (1998) 1.29
Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene (1993) 1.29
Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl (1993) 1.28
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer (2003) 1.25
Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res (2000) 1.23
Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ (1998) 1.22
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res (1999) 1.18
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer (1996) 1.12
Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res (1991) 1.12
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate (1989) 1.11
Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology (1990) 1.07
Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer (1997) 1.04
Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol (1999) 1.04
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate (2001) 0.95
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate (2001) 0.93
Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol (2001) 0.92
Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol Rep (2000) 0.92
Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology (2001) 0.92
Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients. Prostate (2000) 0.89
Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells. Inflamm Res (2005) 0.87
Effect of estrogen withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. Urology (1998) 0.86
Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene (2008) 0.86
Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. Cancer Res (1990) 0.85
Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention. Prostate Cancer Prostatic Dis (2005) 0.83
Biological basis for chemohormonal therapy for prostatic cancer. Cancer Treat Res (1989) 0.81
Future concepts in the medical therapy of benign prostatic hyperplasia. Curr Opin Urol (2001) 0.81
Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy. Surgery (1995) 0.80
Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate (1987) 0.80
Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology (1994) 0.79
Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. J Surg Res (1995) 0.79
Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate (1994) 0.79
The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. Ann N Y Acad Sci (1993) 0.77
Association states of androgen receptors in nuclei of human benign hypertrophic prostate. Prostate (1986) 0.76
Intranuclear distribution of androgen receptors in human prostate carcinoma. J Endocrinol (1987) 0.76
Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urol Res (1987) 0.75
Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer. Cancer Res (1998) 0.75
Reversion of human prostate tumorigenic growth by azatyrosine. Urology (1995) 0.75
New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy. Eur Urol (1990) 0.75
Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol (1993) 0.75
Evaluation of biopsy techniques for androgen receptor assay in human prostatic tissue. Br J Urol (1986) 0.75
Potent in vitro anticancer activities of ring-expanded ("fat") nucleosides containing the imidazo[4,5-e][1,3]diazepine ring system. Nucleosides Nucleotides Nucleic Acids (2001) 0.75
Human hepatocellular carcinoma tumor xenografts. Their androgen-receptor status and growth responses to castration. Dig Dis Sci (1988) 0.75